F2G

About:

F2G discovers and develops novel drugs for the treatment of life-threatening fungal diseases.

Website: http://www.f2g.com

Top Investors: Innovate UK, European Investment Bank, Forbion Capital Partners, Sofinnova Partners, Morningside Venture Investments

Description:

F2G is advancing its own patented compounds and technologies which will lead to the development of novel agents to treat serious fungal disease. The Company was founded on its proprietary genomics technology (MycoBank®) that identifies essential gene targets in fungi. Having received initial funding in 2002 the company then rapidly diversified into chemistry-driven discovery. They have also assembled an experienced development capacity.

Total Funding Amount:

$383M

Headquarters Location:

Manchester, Manchester, United Kingdom

Founded Date:

1998-01-01

Contact Email:

contact(AT)f2g.com

Founders:

David Denning

Number of Employees:

11-50

Last Funding Date:

2024-09-12

IPO Status:

Private

© 2025 bioDAO.ai